$1.45
4.14%
Downside
Day's Volatility :5.45%
Upside
1.37%
41.27%
Downside
52 Weeks Volatility :51.2%
Upside
16.91%
Period | Opko Health, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 14.84% | 1.4% | 0.0% |
6 Months | 13.08% | 3.8% | 0.0% |
1 Year | 9.7% | 15.3% | 0.0% |
3 Years | -64.75% | 11.4% | -27.4% |
Market Capitalization | 1.0B |
Book Value | $2.00 |
Earnings Per Share (EPS) | -0.33 |
PEG Ratio | -2.87 |
Wall Street Target Price | 3.96 |
Profit Margin | -33.93% |
Operating Margin TTM | -33.85% |
Return On Assets TTM | -8.09% |
Return On Equity TTM | -16.59% |
Revenue TTM | 716.4M |
Revenue Per Share TTM | 0.99 |
Quarterly Revenue Growth YOY | -31.4% |
Gross Profit TTM | 214.3M |
EBITDA | -165.5M |
Diluted Eps TTM | -0.33 |
Quarterly Earnings Growth YOY | 0.19 |
EPS Estimate Current Year | -0.3 |
EPS Estimate Next Year | -0.29 |
EPS Estimate Current Quarter | -0.09 |
EPS Estimate Next Quarter | -0.09 |
What analysts predicted
Upside of 173.1%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 990.3M | ↑ 2.51% |
Net Income | -153.0M | ↓ 49.88% |
Net Profit Margin | -15.45% | ↑ 16.15% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 901.9M | ↓ 8.93% |
Net Income | -312.0M | ↑ 103.92% |
Net Profit Margin | -34.59% | ↓ 19.14% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.4B | ↑ 59.15% |
Net Income | 30.6M | ↓ 109.8% |
Net Profit Margin | 2.13% | ↑ 36.72% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.8B | ↑ 23.64% |
Net Income | -29.5M | ↓ 196.45% |
Net Profit Margin | -1.66% | ↓ 3.79% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.0B | ↓ 43.42% |
Net Income | -328.0M | ↑ 1011.86% |
Net Profit Margin | -32.66% | ↓ 31.0% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 863.5M | ↓ 14.01% |
Net Income | -188.9M | ↓ 42.42% |
Net Profit Margin | -21.87% | ↑ 10.79% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 237.6M | ↑ 28.16% |
Net Income | -18.2M | ↓ 78.64% |
Net Profit Margin | -7.66% | ↑ 38.29% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 265.4M | ↑ 11.71% |
Net Income | -19.6M | ↑ 7.91% |
Net Profit Margin | -7.4% | ↑ 0.26% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 178.6M | ↓ 32.71% |
Net Income | -84.5M | ↑ 330.24% |
Net Profit Margin | -47.31% | ↓ 39.91% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 181.9M | ↑ 1.85% |
Net Income | -66.5M | ↓ 21.29% |
Net Profit Margin | -36.56% | ↑ 10.75% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 173.7M | ↓ 4.52% |
Net Income | -81.8M | ↑ 23.05% |
Net Profit Margin | -47.12% | ↓ 10.56% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 182.2M | ↑ 4.89% |
Net Income | -10.3M | ↓ 87.41% |
Net Profit Margin | -5.66% | ↑ 41.46% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 2.5B | ↓ 5.36% |
Total Liabilities | 659.8M | ↓ 11.59% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 2.3B | ↓ 5.79% |
Total Liabilities | 694.5M | ↑ 5.26% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 2.5B | ↑ 7.09% |
Total Liabilities | 801.5M | ↑ 15.41% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.4B | ↓ 2.97% |
Total Liabilities | 714.6M | ↓ 10.84% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 2.2B | ↓ 9.68% |
Total Liabilities | 605.7M | ↓ 15.24% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 2.0B | ↓ 7.18% |
Total Liabilities | 622.5M | ↑ 2.77% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↑ 0.11% |
Total Liabilities | 617.8M | ↑ 2.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↓ 0.49% |
Total Liabilities | 623.6M | ↑ 0.93% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.1B | ↓ 4.73% |
Total Liabilities | 612.1M | ↓ 1.84% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.0B | ↓ 2.19% |
Total Liabilities | 622.5M | ↑ 1.7% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 2.0B | ↓ 1.87% |
Total Liabilities | 721.2M | ↑ 15.86% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 2.0B | ↑ 0.3% |
Total Liabilities | 584.6M | ↓ 18.95% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -109.1M | ↑ 18.53% |
Investing Cash Flow | -26.1M | ↓ 44.03% |
Financing Cash Flow | 140.9M | ↑ 130.84% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -172.5M | ↑ 58.07% |
Investing Cash Flow | -13.3M | ↓ 49.19% |
Financing Cash Flow | 175.2M | ↑ 24.37% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 39.5M | ↓ 122.88% |
Investing Cash Flow | -18.3M | ↑ 38.11% |
Financing Cash Flow | -35.1M | ↓ 120.02% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 38.3M | ↓ 2.89% |
Investing Cash Flow | 35.9M | ↓ 296.15% |
Financing Cash Flow | -10.4M | ↓ 70.49% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -22.6M | ↓ 28.38% |
Investing Cash Flow | -7.7M | ↑ 40.54% |
Financing Cash Flow | -13.1M | ↓ 229.33% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -365.0K | ↓ 98.39% |
Investing Cash Flow | -5.5M | ↓ 28.85% |
Financing Cash Flow | 3.5M | ↓ 126.39% |
Sell
Neutral
Buy
Opko Health, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Opko Health, Inc. | 1.38% | 13.08% | 9.7% | -64.75% | -2.65% |
Idexx Laboratories, Inc. | -10.37% | -12.46% | 0.22% | -33.24% | 60.91% |
Agilent Technologies Inc. | -4.25% | -2.47% | 24.64% | -14.39% | 81.5% |
Thermo Fisher Scientific, Inc. | -6.54% | -2.3% | 21.87% | -10.38% | 90.67% |
Danaher Corp. | -7.82% | -0.4% | 24.97% | -17.78% | 84.21% |
Iqvia Holdings Inc. | -1.82% | -3.44% | 10.58% | -12.03% | 60.51% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Opko Health, Inc. | NA | NA | -2.87 | -0.3 | -0.17 | -0.08 | NA | 2.0 |
Idexx Laboratories, Inc. | 40.05 | 40.0 | 4.38 | 10.56 | 0.59 | 0.23 | NA | 19.72 |
Agilent Technologies Inc. | 29.07 | 29.07 | 3.01 | 5.24 | 0.25 | 0.08 | 0.01 | 20.53 |
Thermo Fisher Scientific, Inc. | 34.96 | 34.85 | 2.13 | 21.69 | 0.13 | 0.05 | 0.0 | 128.08 |
Danaher Corp. | 46.73 | 46.74 | 2.94 | 7.5 | 0.08 | 0.04 | 0.0 | 71.03 |
Iqvia Holdings Inc. | 27.61 | 27.61 | 1.06 | 11.15 | 0.22 | 0.05 | NA | 38.37 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Opko Health, Inc. | Buy | $1.0B | -2.65% | NA | -33.93% |
Idexx Laboratories, Inc. | Buy | $33.9B | 60.91% | 40.05 | 22.53% |
Agilent Technologies Inc. | Buy | $40.3B | 81.5% | 29.07 | 21.75% |
Thermo Fisher Scientific, Inc. | Buy | $213.4B | 90.67% | 34.96 | 14.48% |
Danaher Corp. | Buy | $179.0B | 84.21% | 46.73 | 16.39% |
Iqvia Holdings Inc. | Buy | $38.6B | 60.51% | 27.61 | 9.17% |
Insights on Opko Health, Inc.
Revenue is up for the last 2 quarters, 173.68M → 182.18M (in $), with an average increase of 4.7% per quarter
Netprofit is up for the last 2 quarters, -81.83M → -10.30M (in $), with an average increase of 694.1% per quarter
In the last 1 year, Danaher Corp. has given 25.0% return, outperforming this stock by 15.3%
In the last 3 years, Opko Health, Inc. has experienced a drawdown of -63.9%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 48.7%
Rubric Capital Management LP
BlackRock Inc
Vanguard Group Inc
State Street Corp
Geode Capital Management, LLC
Amvescap Plc.
opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig
Organization | Opko Health, Inc. |
Employees | 3930 |
CEO | Dr. Phillip Frost Ph.D. |
Industry | Health Technology |
Cactus Acquisition Corp 1 Ltd
$1.45
-1.36%
Rigel Resource Acquisition Corp
$1.45
-1.36%
Ft Energy Income Partners Strategy Etf
$1.45
-1.36%
Tian Ruixiang Holdings Ltd
$1.45
-1.36%
Invsc Bulletshares 2032 Corp
$1.45
-1.36%
Schwab International Dividend Equity Etf
$1.45
-1.36%
Fitell Corp
$1.45
-1.36%
Estrella Immunopharma Inc
$1.45
-1.36%
Abrdn Income Credit Strategies Fund
$1.45
-1.36%